致癌性EZH2突变体的综合多态学分析:从表观遗传重编程到分子特征
Julian Aldana1,2, Miranda L Gardner1,2, Michael A Freitas1,2
1Ohio State Biochemistry Program, Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA.
International journal of molecular sciences
|July 29, 2023
概括
肠道同源增强剂2 (EZH2) 的体质突变在白血病和淋巴瘤中失调细胞过程. 这项研究揭示了EZH2突变如何影响基因表达,蛋白质网络和新陈代谢,提供了新的治疗点.
科学领域:
- 表观遗传学和分子生物学
- 癌症基因组学 癌症基因组学
- 系统生物学 系统生物学
背景情况:
- 在增强体同源2 (EZH2) 的体性异构基因突变在扩散性大B细胞淋巴瘤 (DLBCL) 和急性髓性白血病 (AML) 中很常见.
- 这些突变破坏了EZH2的甲基转移酶活性,影响了基因素H3 lysine 27 (H3K27) 甲基化和下游细胞功能.
- 功能获取 (GOF) 和功能丧失 (LOF) 突变改变染色质结构,蛋白质相互作用和基因转录.
研究的目的:
- 为了全面描述由特定的EZH2突变引起的差异H3K27me3沉积的多奥米克效应.
- 为了识别受EZH2GOF和LOF突变影响的基因,蛋白质网络和代谢途径.
- 为了阐明EZH2介导的细胞转变从表观遗传变化到血液恶性瘤的表型结果.
主要方法:
- 使用了一种多omics方法,包括EpiProfile,H3K27me3 CUT&Tag,ATAC-Seq,转录组学,蛋白组学和代谢组学.
- 研究了三个稳定的同位素EZH2突变:Y641F (GOF),A677G (LOF) 和H689A/F667I (LOF).这些突变包括:
- 进行系统生物学分析,以整合表观遗传,转录基因,蛋白质基因和代谢基因数据.
主要成果:
- 确定了由EZH2 GOF和LOF突变物影响的不同基因组和下游目标.
- 观察到对关键细胞通路的影响,包括增殖,分化和迁移.
- 揭示了蛋白质网络和支持异常细胞行为的代谢特征的破坏.
结论:
- 在血液恶性瘤中,EZH2突变会导致显著的表观遗传和表型变化.
- 这项研究为系统层面的理解提供了突变EZH2如何影响细胞过程的理解.
- 确定了改善EZH2突变血液癌症的诊断和治疗的潜在目标.
更多相关视频
10:41An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
Published on: April 5, 2018
10.4K
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
2.8K
相关概念视频
Epigenetic Regulation
31.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.1K
Cancers Originate from Somatic Mutations in a Single Cell
12.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K
